Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).

MLA

Schenkel, Jason M., et al. “Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).” American Journal of Clinical Pathology, vol. 151, no. 6, May 2019, pp. 584–92. EBSCOhost, https://doi.org/10.1093/ajcp/aqz004.

APA

Schenkel, J. M., Hergott, C. B., Dudley, G., Drew, M., Charest, K., & Dorfman, D. M. (2019). Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS). American Journal of Clinical Pathology, 151(6), 584–592. https://doi.org/10.1093/ajcp/aqz004

Chicago

Schenkel, Jason M, Christopher B Hergott, Graham Dudley, Mai Drew, Karry Charest, and David M Dorfman. 2019. “Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).” American Journal of Clinical Pathology 151 (6): 584–92. doi:10.1093/ajcp/aqz004.